Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
RNAZ
RNAZ
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RNAZ News
Biotech Companies See Significant Stock Gains
Jun 11 2026
NASDAQ.COM
TransCode to Host Live Webcast on TTX-MC138 Phase 2a Trial and Pipeline
Jun 08 2026
PRnewswire
Biotech Stocks Pre-Market Trading Insights
Jun 03 2026
NASDAQ.COM
TransCode Advances TTX-MC138 to Phase 2 Trials for ctDNA-Positive Cancers
Jun 03 2026
PRnewswire
TransCode Initiates Phase 2a Clinical Trial for TTX-MC138
May 27 2026
PRnewswire
TransCode Appoints New Chair of Scientific Advisory Board
Apr 27 2026
PRnewswire
TransCode Secures $20 Million Financing for Cancer Treatment
Apr 07 2026
PRnewswire
TransCode Secures $20 Million Financing Agreement
Apr 07 2026
Newsfilter
TransCode Enters Exclusive License Agreement with Unleash Immuno Oncolytics
Mar 03 2026
PRnewswire
TransCode Publishes Novel Tumor Immunotherapy Research
Feb 23 2026
PRnewswire
TransCode Publishes TTX-MC138 Research for Glioblastoma Treatment
Jan 06 2026
PRnewswire
TransCode's TTX-MC138 Significantly Extends Survival in Glioblastoma Mouse Models
Jan 06 2026
Newsfilter
TransCode Appoints Jack E. Stover to Board of Directors, Enhancing Leadership Experience
Dec 22 2025
PRnewswire
TransCode Appoints Jack E. Stover to Board, Enhancing Oncology Expertise
Dec 22 2025
Newsfilter
TransCode's TTX-MC138 Set to Begin Phase 2a Trial Within Quantum Leap PRE-I-SPY Initiative
Dec 12 2025
NASDAQ.COM
TransCode Partners with Quantum Leap for TTX-MC138 Phase 2a Clinical Trial
Dec 11 2025
Newsfilter
Show More News
